Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Vistra Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.46 (market cap $12.58B), while Vistra Corp trades at $160.38 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 4.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Vistra Corp pays a 0.59% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Vistra Corp for 32 Days on average.
| HALO | VST | |
|---|---|---|
Market Cap | $12.58B | $52.41B |
Volume | 2,179,278 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $115.22 | $210.85 |
52-Week Low | $61.63 | $134.71 |
Typical Hold Time | 0 Days | 32 Days |
Enterprise Value | $14.49B | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vistra Corp (VST) trades at $156.19, down 6.32% today, but maintains strong analyst support with 91% buy ratings and a $215.23 consensus target. The stock shows bullish technical signals with support at $152 and resistance at $164, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Vistra presents compelling growth potential as a key beneficiary of AI infrastructure expansion, with strong profitability metrics and institutional backing. However, investors face risks from volatile earnings performance (two recent EPS misses) and execution challenges in capital-intensive energy projects. The stock's current discount to analyst targets offers upside potential if the company can consistently deliver on its nuclear expansion and data center power contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
